Black Rock Inc. Cognition Therapeutics Inc Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Black Rock Inc. holds 152,581 shares of CGTX stock, worth $77,816. This represents 0.0% of its overall portfolio holdings.

Number of Shares

152,581

Previous 55,820 173.34%

Holding current value

$77,816

Previous $101,000 150.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.66 - $2.62 $160,623 - $253,513	96,761 Added 173.34%	152,581 $253,000
Q1 2024 May 10, 2024	BUY	$1.78 - $2.53 $375 - $533	211 Added 0.38%	55,820 $101,000
Q4 2023 Feb 13, 2024	SELL	$0.96 - $2.42 $599 - $1,510	-624 Reduced 1.11%	55,609 $102,000
Q3 2023 Nov 13, 2023	SELL	$1.25 - $1.9 $2,730 - $4,149	-2,184 Reduced 3.74%	56,233 $80,000
Q2 2023 Aug 11, 2023	BUY	$1.56 - $3.38 $32,257 - $69,891	20,678 Added 54.79%	58,417 $106,000
Q1 2023 May 12, 2023	BUY	$1.51 - $2.3 $1,694 - $2,580	1,122 Added 3.06%	37,739 $74,000
Q4 2022 Feb 13, 2023	BUY	$1.17 - $3.51 $7,970 - $23,910	6,812 Added 22.86%	36,617 $76,000
Q3 2022 Nov 14, 2022	BUY	$1.63 - $3.6 $3,742 - $8,265	2,296 Added 8.35%	29,805 $56,000
Q2 2022 Aug 12, 2022	BUY	$1.5 - $3.45 $28,836 - $66,322	19,224 Added 232.03%	27,509 $58,000
Q1 2022 May 12, 2022	BUY	$2.41 - $6.9 $694 - $1,987	288 Added 3.6%	8,285 $23,000
Q4 2021 Feb 10, 2022	BUY	$5.1 - $12.98 $40,784 - $103,801	7,997 New	7,997 $51,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

6.5M

Call Options Held

Put Options Held

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $11.6M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account